RESEARCH DIGEST / ABOUT
About MD NAD+
An independent editorial reading of the NAD+ research record — what the studies measured, stamped to source.
What this site is
MD NAD+ is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ and its precursors. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The site reads like a specimen sheet on purpose: each finding is a stamped readout tied to a study, with the effect sizes, doses, and routes set in plain view and the gaps marked as plainly as the results. The aim is a fiduciary digest of what the NAD+ literature actually measured — not a promise, not a protocol, and not a product.
What the 'MD' means here
The 'MD' in the name is editorial framing, not a clinical claim. It signals the posture this publisher takes toward the literature — reading the research with the seriousness a clinical record deserves — not a statement that the site offers diagnosis, treatment, consultation, or prescriptions. There is no doctor behind this page, no clinical team, and no telehealth pathway. NAD+ is not a prescription medicine, and nothing here is dispensed, priced, or sold.
How we handle the evidence
We report only what specific cited studies measured, and we keep the NAD+-versus-precursor distinction exact: a trial of oral NMN or NR is a precursor trial, never described as 'taking NAD+' [4][1]. We separate the well-supported findings — that oral precursors raise blood NAD+ — from the unsettled ones, including the limited human clinical-outcome evidence flagged in a 2025 Nature Metabolism review [15], the rapid plasma clearance and weak controlled evidence for IV NAD+ [11], and the contested FDA position on NMN's supplement status. Where the literature stops, we stop.
Regulatory posture
NAD+ and its precursors (NMN, NR, nicotinamide) are sold as dietary supplements, not approved drugs, and are not prohibited by WADA. Some precursor forms — notably NMN — face an unsettled FDA challenge to their dietary-supplement status, which we present as a marketplace dispute rather than a claim that any product is banned. IV/injectable NAD+ is a compounded, unapproved wellness therapy with a documented Class I recall for endotoxin contamination. We state these facts to keep the regulatory picture accurate, and we make no recommendation to use any product or dose.